|
Match
|
Document |
Document Title |
|
|
7465709 |
Structural formulas based on the repetitive motifs of salivary proline rich proteins mucin and collagen designed to modulate cell and tissue growth division and differentiation
Computational analysis was used to derive structural peptide formulas SALIVAR, SALIVAL, SALIVAN characterizing common repetitive fragments that reconstruct a large number of salivary proline rich...
|
|
|
7452868 |
Controlled release formulations of octreotide
A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two...
|
|
|
7452867 |
Use of ADNF polypeptides for treating peripheral neurotoxicity
This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also...
|
|
|
7435790 |
Dihydroxypropyl cysteine peptide and agent containing this peptide
The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following...
|
|
|
7432245 |
Pharmaceutical formulation comprising a peptide angiogenesis inhibitor
Parenteral formulations of peptides which are useful for sustained release are disclosed. Also disclosed are methods of preparation for the formulations.
|
|
|
7427598 |
Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
The present invention provides methods for improving performance (e.g. learning and/or memory) using (ADNF) polypeptides, by treating the subject prenatally or postnatally with an Activity...
|
|
|
7425541 |
Enzyme-cleavable prodrug compounds
The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is...
|
|
|
7423011 |
Therapeutic chemokine receptor antagonists
The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for...
|
|
|
7423020 |
Treatment of mood disorders by administration of SMR1
This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central...
|
|
|
7414029 |
Antagonistic peptides of prostaglandin E2 receptor subtype EP4
Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal...
|
|
|
7407938 |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
One embodiment of the invention relates to compounds of the formula I,
in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate...
|
|
|
7408028 |
Peptides, antibodies thereto, and their use in treatment of central nervous system, damage
The application provides peptides that interact with the inhibitory domains of the myelin proteins Nogo, TNR, and MAG. These may be used in the treatment of CNS damage, and for the development of...
|
|
|
7407939 |
Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics
The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate...
|
|
|
7405203 |
Pharmaceutical compositions including low dosages of desmopressin
The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a...
|
|
|
7405200 |
Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and...
|
|
|
7404948 |
Peptidic conjugates for alopecia prevention and treatment
The invention relates to novel peptidic conjugates containing a Gly-His-Lys sequence and used for dermatology or cosmetology for stimulating hair growth or stopping hair fall.
|
|
|
7405194 |
Therapeutic agents and methods of use thereof for the treatment of melanoma
The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis...
|
|
|
7402558 |
Method for aiding implantation or decreasing miscarriage rate
The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG or LH, or a bio-analogue thereof, is administered during the...
|
|
|
7402559 |
Composition and method of treatment for urogenital conditions
The present invention is directed to a composition and method for treating uro-genital conditions. One embodiment disclosed is a pharmaceutical composition for use in the treatment of uro-genital...
|
|
|
7396814 |
Metallopeptide compositions for treatment of sexual dysfunction
Metallopeptide compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The...
|
|
|
7393834 |
LHRH-antagonists in the treatment of fertility disorders
A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing...
|
|
|
7390788 |
Peptide pharmaceutical compositions
The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity,...
|
|
|
7381704 |
Methods for use of short bioactive peptides
Short bioactive peptides containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological...
|
|
|
7378396 |
Therapeutic agents and methods for cardiovascular disease
The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO)...
|
|
|
7374898 |
Peptide inhibitors against seprase
The invention generally relates compositions and methods for the treatment of patients with melanoma and other malignant cancers. The compositions of the present invention are novel peptide...
|
|
|
7368119 |
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
|
|
|
7368429 |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire...
|
|
|
7361634 |
Pain-sensitive therapeutic wound dressings
The invention provides a wound dressing comprising a therapeutic agent and a matrix comprising polymers joined by cross-linkages which cross-linkages comprise oligopeptidic sequences which are...
|
|
|
7354903 |
Cosmetic compositions containing short bioactive peptides
Short bioactive peptides containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological...
|
|
|
7348307 |
Methionine aminopeptidase-2 inhibitors and methods of use thereof
The present invention provides methods of treating a lymphoma (e.g., a T-cell lymphoma or a B-cell lymphoma) in a subject by administering to the subject a therapeutically effective amount of one...
|
|
|
7345022 |
Anti-fibril peptides
Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's...
|
|
|
7338938 |
Methods for treating a patient undergoing chemotherapy
The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and...
|
|
|
7326686 |
Compounds and methods for regulating cell adhesion
Methods for using modulating agents to enhance or inhibit cadherin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. In particular, the modulating agents may be...
|
|
|
7317003 |
Small peptides having anti-angiogenic and endothelial cell inhibition activity
The present invention provides peptides having potent anti-angiogenic activity and endothelial cell proliferation inhibition activity. The peptides can be administered as pharmaceutical...
|
|
|
7314865 |
Compositions and methods for promoting lipid mobilization in humans
The invention provides methods of using polypeptide compounds based on the structures of insect peptides of the adipokinetic hormone family to mobilize lipids in humans. The compositions and...
|
|
|
7311892 |
Multidrug multiligand conjugates for targeted drug delivery
Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite...
|
|
|
7309691 |
Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders
The invention relates to a pharmaceutical combined preparation of LHRH analogues and anti-oestrogens having tissue-selective oestrogen activity and also to its use for the treatment of...
|
|
|
7307063 |
Melanocortin metallopeptides for treatment of sexual dysfunction
Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The...
|
|
|
7294615 |
Compounds that associate on the intermolecular level and aggregate bodies that contain them
Compound of the general formula (I)
X(B) m (I)
wherein
X is an m-valent...
|
|
|
7291599 |
Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases
The invention relates to a process for the treatment of neurodegenerative diseases wherein mis-folded proteins accumulate in characteristic lesions and contribute substantially to a pathogenesis...
|
|
|
7288522 |
Method of promoting erythropoiesis
The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with...
|
|
|
7285525 |
Suppression of immune response via inhibition of cathepsin S
Methods and products for suppressing a class II MI-IC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by...
|
|
|
7285264 |
Peptide-based body surface coloring reagents
Peptides have been identified that bind with high affinity to body surfaces, such as, hair, skin, nails, teeth, gums, and oral cavity surfaces. Diblock and triblock peptide-based body surface...
|
|
|
7265093 |
Drug therapy for Celiac Sprue
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the...
|
|
|
7262169 |
Process for preparing peptide intermediates
The present invention is directed to the improved synthesis of compounds of formula (I) an intermediate compound which is useful in the synthesis of the anticancer agents known as PSA conjugates.
|
|
|
7262163 |
Short amphipathic peptides with activity against bacteria and intracellular pathogens
“Minimalist” antimicrobial peptides are disclosed based on 50 to 80% α,α-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar...
|
|
|
7258996 |
Metalloproteinase inhibitory agent
The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent of casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The...
|
|
|
7256174 |
Somatostatin and somatostatin agonists for treating insulin insensitivity and Syndrome X
The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition...
|
|
|
7252829 |
HLA binding peptides and their uses
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles...
|
|
|
7244708 |
Inhibitors of memapsin 2 and use thereof
Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been...
|